Metabolic Health
Tirzepatide for MASH: Phase 2 Signals Reshape the Liver-Metabolic Playbook
A dual GIP/GLP-1 agonist already changing diabetes and obesity care is now posting credible early signals against the fatty-liver disease that often travels with them.